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Abbreviations and Textual Footnotes  
2-AG - 2-arachidonoylglycerol; AA – Arachidonic acid; CB – cannabinoid; DAGL – Diacylglycerol 
Lipase; DiFMUO - 6, 8-difluoro-4-methylumbelliferyl-octanoate; eCB – endocannabinoid; GST - 
glutathione S-transferase; GST-DAGLβ CD - glutathione S-transferase diacylglycerol lipase β 
catalytic domain; PNPB - p-nitrophenyl butyrate; Sf9 - Spodoptera frugiperda; THL - 
tetrahydrolipstatin 
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Abstract  
The diacylglycerol lipases (DAGLα and DAGLβ) hydrolyse DAG to generate 2-
arachidonoylglycerol (2-AG), the principal endocannabinoid and main precursor of 
arachidonic acid (AA). The DAGLs make distinct tissue specific contributions towards 2-AG 
and AA levels and therefore selective modulators for these enzymes could play crucial roles 
towards harnessing their therapeutic potential. Relatively high-throughput assays have 
recently been reported for DAGLα and have proven useful towards the characterization of 
inhibitors of this enzyme. Similar assays are also warranted for DAGLβ which was the aim of 
this study. We first adapted previously reported DAGLα membrane assays (using PNPB and 
DiFMUO as substrates) to measure recombinant DAGLβ activity in membranes. In contrast 
to results with DAGLα, both substrates provided a relatively limited signal window for 
measuring DAGLβ activity, however, an improved window was obtained when employing a 
third commercially available substrate, EnzChek. In order to further improve on the assay 
parameters, we successfully purified the glutathione S-transferase (GST) tagged catalytic 
domain of DAGLβ. Activity of the enzyme was confirmed using EnzChek as well as two 
DAGL inhibitors (THL and OMDM-188). The purified DAGLβ catalytic domain assay 
described here provides the basis for a relatively clean and convenient assay with the 
potential to be adapted for high-throughput drug discovery efforts. 
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Introduction 
The diacylglycerol lipases (DAGLα and DAGLβ) generate a signalling pool of 2-
arachidonoylglycerol (2-AG) for endocannabinoid (eCB) signalling via the CB1 and/or CB2 
receptors which serves numerous functions during development and in the adult. For 
example, DAGL-dependent eCB signalling regulates axonal growth and guidance during 
development 
1–6
. In the adult two forms of plasticity are controlled by DAGL-dependent eCB 
signalling and these are synaptic plasticity in the form of retrograde synaptic transmission 
throughout the brain 
7,8
 and cellular plasticity in the form of adult neurogenesis in the 
hippocampus and sub-ventricular zone 
1,7,9,10
.  The DAGLs have a second important function, 
and this is the generation of 2-AG as a substrate for monoacylglycerol lipase (MAGL) to 
maintain arachidonic acid (AA) levels in various tissues including the brain, liver and adipose 
7,11,12
.  
The DAGLs are emerging as interesting therapeutic targets 
13–15
. In this context, DAGL 
activity drives eCB signalling and drugs that modulate other steps in this pathway have 
shown beneficial effects in obesity 
16–19
 and pain 
20,21
 amongst many other diseases 
22
. More 
recently, the DAGL-MAGL pathway has been implicated to operate independently of the 
eCB pathway in inflammatory responses associated with Alzheimer's disease 
23
, Parkinson's 
disease 
24
 and peripheral inflammation 
13,24
.  It is noteworthy that DAGLα and DAGLβ make 
distinct tissue specific contributions towards 2-AG and AA levels and therefore selective 
modulators for these enzymes are likely to be essential to harness their therapeutic potential 
from both a safety and efficacy perspective 
7,25
. For instance, recent studies have highlighted 
DAGLβ as a target for inflammatory diseases via mechanisms independent of the 
cannabinoid receptors whereas DAGLα is responsible for 2-AG mediated CB1 signalling at 
the synapse and therefore non-selectively targeting DAGLβ (over DAGLα) could risk 
Page 4 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5 
 
disrupting CB1 signalling at the synapse 
13,23–25
. It is therefore crucial to factor in selectivity 
assays to address this in drug discovery programmes. 
Over the years, a wide range of assays have been developed to measure DAGL activity which 
have been utilized for the characterization, discovery and/or development of established as 
well as novel DAGL inhibitors. Mass spectrometry based assays that utilise synthetic DAG as 
the native substrate and the measurement of 2-AG as the product have been reported 
26,27
. A 
thin layered chromatography based radio-assay involving radio-labelled DAG has also been 
utilized to measure DAGL activity 
2,28
. Several fluorescently labelled activity based probes 
with applications in gel based assays have been developed for the DAGLs, ranging from the 
generic serine hydrolase binding probe – fluorophosphonate 
27
 to more recent probes with 
ever improving selectivity for DAGLα and DAGLβ 
13,29,30
. Recently, higher throughput 
assays suitable for drug-discovery programs for the DAGLs have been reported. Johnston et 
al reported on a fluorescence resonance energy transfer assay using ether lipid reporters and 
which is of particular utility when using DAGLs purified to homogeneity (due to hydrolysis 
by non DAGL enzymes in crude samples) 
28
. Van der Wel et al reported on a DAGLα native 
substrate assay using a coupled enzyme approach adapted from a previously reported MAGL 
assay 
31,32
. Pedicord et al., reported on simple economical recombinant DAGLα membrane 
based assays utilizing the fluorogenic 6, 8-difluoro-4-methylumbelliferyl-octanoate 
(DiFMUO) and  the chromogenic p-nitrophenyl butyrate (PNPB) as surrogate substrates 
33,34
.  
Similar assays are also warranted for DAGLβ and so in the present study, we focussed on the 
development of DAGLβ activity assays to further complement the currently available panel 
of DAGL assays for drug discovery programmes. We first generated and characterized a 
clonal line of human U2OS osteosarcoma cells transfected with a construct expressing the 
epitope (V5) tagged human DAGLβ transgene for expression of the recombinant enzyme.  
We attempted to adapt previously reported DAGLα membrane assays (using PNPB and 
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DiFMUO as substrates) to measure DAGLβ activity using membranes prepared from these 
cells but with limited success due to relatively modest signal windows.  However, a much 
improved window was obtained using a third commercially available substrate, EnzChek. In 
order to further improve on the assay parameters, we successfully purified the N-terminally 
glutathione S-transferase (GST) tagged catalytic domain of DAGLβ, which in conjunction 
with EnzChek, provided the basis for a relatively clean, convenient, and high-throughput 
assay and thereby an attractive tool for drug discovery and development efforts. 
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Experimental Procedures (Materials and Methods) 
Reagents 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. 
 
Generation of cell line stably expressing DAGLα/β with a C-terminal V5 tag 
Full length human DAGLα/β was cloned into the pcDNA6.2/V5-DEST vector (Invitrogen) to 
enable expression of the transgene with a C-terminal V5 tag. These constructs were 
individually transfected (Lipofectamine 2000, Invitrogen) into a human U2OS osteosarcoma 
cell line that for the purpose of future studies was also genetically modified to express a CB1 
receptor reporter construct (Tango™ CNR1-bla U2OS cells from Invitrogen) and stable 
transfected clones were selected using blasticidin (4µg/ml). The cell lines stably expressing 
DAGLα-V5 (V5α11) or DAGLβ-V5 (V5β4) were subsequently established following 
verification by Western blotting and immunocytochemical analyses using a V5 antibody 
(mouse, Invitrogen).    
 
Membrane preparation 
Membranes were prepared following a previously published method 
33
. Briefly, cells cultured 
in 10cm dishes (~90% confluent) were scraped in 1ml (per dish) of lysis buffer (20mM 
HEPES pH7.0, 2mM DTT, 0.25M sucrose, 10mM NaF, 1mM Na3VO4 and 1x Roche 
'Complete' protease inhibitor) and then homogenised on ice using a Polytron (PT 1200 E) 
homogeniser (three 7 seconds bursts at the maximum setting with 30 seconds interval in 
between). The homogenates were then subjected to centrifugation at 100,000g for 30 minutes 
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at 4°C. The supernatants were discarded and the pellets (membrane preparations) were 
resuspended in 200µl of sucrose free lysis buffer, using the homogeniser. Membrane aliquots 
were stored at -80°C. 
 
Immunocytochemistry 
Cells (10,000/well) were seeded onto poly-lysine coated coverslips and cultured overnight 
after which they were fixed in 4% paraformaldehyde for 30 minutes at room temperature. 
The fixed cells were washed three times with phosphate buffered saline (PBS) and then 
permeabilised with 0.2% Triton X-100-PBS for 10 minutes. The permeabilised cells were 
washed three times with PBS, blocked with 1% BSA-PBS (block solution) for 30 minutes 
and then incubated with a V5 antibody (mouse, Invitrogen, diluted 1/1000 in block solution) 
for 1 hour at room temperature. The cells were then washed with PBS and incubated for a 
further hour with an AlexaFluor 488 secondary antibody (mouse, Invitrogen, diluted 1/2000 
in block solution) and the nuclear stain Hoechst 33258 (Invitrogen, diluted 1/10,000 in block 
solution). After three washes with PBS, the coverslips were mounted onto microscope slides 
and images of the immunostained cells were collected using the Carl Zeiss LSM 710 
microscope and the Carl Zeiss Zen software (version 1.0.1.0). 
 
Expression and purification of DAGLβ catalytic domain 
The human DAGLβ catalytic domain sequence corresponding to amino acids 228-672 was 
cloned into the pDEST20 vector (Invitrogen) to enable expression of the DAGLβ catalytic 
domain with an N-terminus GST tag (GST-DAGLβ CD) using the baculovirus expression 
system. For the baculovirus generation and expression Sf9 (Spodoptera frugiperda) insect 
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cells along withSF-900 II SFM media (Invitrogen) were used. Recombinant baculoviruses 
(P1) were generated and amplified using the Sf9 cells and the GST-DAGLβ CD pENTR 
construct following the Bac-to-Bac system (Invitrogen). In order to amplify the virus, 200mls 
Sf9 cells at a density of 1.2 x 10
6
 cells/ml in 1L Erlenmeyer flasks were infected with 500µl 
of P1/2 virus and incubated in a shaker at 27.5°C (110rpm) for 4-5 days (or until viability 
<80%). The P2/3 virus (supernatant) was then collected by centrifugation (3,000g for 10 
minutes). The viruses were stored in the dark at 4°C in the presence of 5% foetal calf serum. 
For expression, 10ml P2/3 virus was added to 200ml Sf9 cells at a density of 2 x 10
6
 cells/ml 
(in 1L Erlenmeyer flask). The cells were cultured for 48 hours (27.5°C and 110rpm) and then 
harvested by centrifugation at 3000g. Cell count at the time of harvest was generally ~3-4 x 
10
6
/ml (~75% viable). 
 
Purification of the GST tagged DAGLβ catalytic domains  
Cell lysis: 3 x 10
9
 cells were resuspended (0.5 x 10
8
 cells/ml) in lysis buffer (50mM Tris, 
150mM NaCl, 2mM DTT, 1% Triton-X-100, pH 7.8) by vortexing and then lysed by dounce 
homogenisation (10 strokes). Lysates were incubated in the cold room on a roller for 2 hours. 
The lysates were then centrifuged at 75,000g for 60 minutes and the supernatant was 
collected. 
GST affinity purification: GST purifications were performed using glutathione sepharose 4B 
beads (GE healthcare). 1ml of settled beads were equilibrated in lysis buffer and then 
incubated with the lysates in the cold room on a roller for 30 minutes. The beads were then 
collected using a plastic drip column. The collected beads were washed with 20 column 
volume wash buffer (50mM Tris, 150mM NaCl, 2mM DTT, 0.05% Triton-X-100, pH 7.8) 
and then 0.5ml elution fractions were collected using the elution buffer (50mM Tris, 150mM 
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NaCl, 2mM DTT, 0.05% Triton-X-100, 50mM glutathione, pH 7.8). The elutions obtained 
were analysed by Coomassie stained SDS-PAGE and typically elutions 2-5 were stored at -
80°C and used for the gel filtration chromatography. 
Gel filtration purification: The purification buffer used for the gel filtration chromatography 
was 50mM Tris, 150mM NaCl, 2mM DTT, 0.05% Triton-X-100, pH 7.8. Gel filtration 
purifications were performed using an Akta prime (GE healthcare) at a flow rate of 
1ml/minute using the HiLoad 16/600 Superdex 200 pg column (GE healthcare). The column 
was equilibrated in 1 column volume of purification buffer after which 2ml (~2mg) of the 
GST elutions was loaded and 1ml fractions were collected. Fractions corresponding to 
individual peaks in the chromatogram (A280) were pooled and analysed by Coomassie 
stained SDS-PAGE (20µl sample). A chromatogram (provided by the manufacturer) of 
protein standards separated using this column was used to determine the approximate 
molecular weights of the fractions obtained following the gel filtration purification. Purity 
was estimated using Coomassie stained gels and the ImageJ software by calculating the 
percentage of the total peak sizes attributed to the band corresponding to GST-DAGLβ CD. 
 
Western blotting 
Samples were diluted using water and 5x SDS protein loading buffer to a concentration of 
1µg/µl and then denatured by boiling for 5 minutes. 10µg of the denatured samples were 
resolved by SDS-PAGE (4% stacking and 10% resolving tris-glycine gels) at a setting of 100 
volts for ~2 hours. The resolved proteins on the gel were transferred (wet transfer) to a 
nitrocellulose membrane (GE healthcare) for 1 hour at 100 volts (4°C). Following the 
transfer, membranes were blocked for 1 hour at room temperature in PBS 5% milk and then 
incubated overnight at 4°C with the primary antibody (V5 (mouse; Invitrogen) or GST 
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(rabbit; Millipore) antibody) diluted 1/1000 in PBS 0.1% Tween (PBST) 2% milk. The 
membranes were then washed in PBST (three times for 10 minutes) and incubated for 1 hour 
at room temperature with the corresponding mouse IR-Dye 680 or rabbit IR-Dye 800 
secondary antibody (LI-COR, diluted 1/5000 in PBST 2% milk). Following this, the 
membranes were washed in PBST (4 times, 10 minutes each) and then PBS (1 time for 10 
minutes). The membranes were visualised using the Odyssey imaging system (LI-COR). β-
actin (rabbit antibody, Abcam) was also detected as a loading control for the cell membranes. 
 
Assays 
96-well clear polypropylene plates were used for the assays. The PNPB and DiFMUO 
(Invitrogen) membrane assays were performed as previously described with some 
modifications 
33
. The assay buffer for the PNPB membrane assay was 50mM HEPES pH 7.5, 
5% DMSO and for the DiFMUO assay - 50mM MES pH 6.5, 5% DMSO. Membranes were 
typically diluted to 4x the final assay concentration (FAC) using the assay buffer, and then 
50µl/well was dispensed. 50µl of the drug (4x FAC, diluted using assay buffer) or assay 
buffer was then added to the membranes followed by 5 minute incubation at room 
temperature. The substrate (DiFMUO or PNPB) was diluted to 40x FAC using DMSO and 
then to 2x FAC using the assay buffer without DMSO. 100µl of the diluted substrate was 
added to each well and the plates were read. For the PNPB assay, the OD400 was measured 
every 12 seconds for 30 minutes using a Spectramax plate reader (Molecular Devices). For 
the DiFMUO assay, the fluorescence (excitation 360nm, emission 450nm) was measured 
every 30 seconds for 30 minutes using the FlexStation (Molecular Devices). The total assay 
volume was 200µl containing 12.5µg/ml membranes, 250µM PNPB or 10µM DiFMUO and 
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5% DMSO. The reaction rates were calculated over the first 10 minutes (linear) using 3 
replicate wells.  
For the EnzChek (Invitrogen) assay, membranes or GST-DAGLβ CD were typically diluted 
to 4x FAC using 50mM HEPES pH 7.5, 5% DMSO (assay buffer) and then 50µl was 
dispensed in each well. 50µl of the drug (4x FAC) or assay buffer was added to the wells and 
the plate was then incubated for 5 minutes at room temperature. The substrate EnzChek was 
diluted to 40x FAC using DMSO and then to 2x FAC using the assay buffer without DMSO. 
100µl of the diluted substrate was added to each well and the fluorescence (excitation 480nm, 
emission 540nm) was measured every 48 seconds for 10 minutes using the FlexStation. The 
total assay volume was 200µl, typically containing 12.5µg/ml membranes or specified 
amount of GST-DAGLβ CD, 2µM EnzChek, and 5% DMSO. The reactions rates were 
typically calculated over the first 2 minutes (linear) using 3 replicate wells. Km and Vmax were 
determined using the SigmaPlot v13 software (Systat Software Inc.) and Michaelis–Menten 
equation.  
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Results 
 
DAGLβ activity membrane assay  
To support the development of a DAGLβ assay, a U2OS cell line stably expressing DAGLβ-
V5 was established following verification by both Western and immunocytochemistry 
analyses using a V5 antibody (Figure 1A and B). Stable expression of DAGLβ-V5 was 
confirmed beyond 30 passages in this cell line (V5β4).We measured the activity of 
membranes derived from V5β4 as well as parental controls using the previously reported 
DAGLα surrogate substrates PNPB and DiFMUO 
33
. Following optimisation of various 
parameters including assay buffer constituents and the substrate and membrane 
concentrations a relatively modest but significant 2-fold difference in the tetrahydrolipstatin 
(THL) sensitive activity was detected between the V5β4 and parental membranes when using 
PNPB as the substrate (Figure 1C) whereas no significant difference in activity was observed 
when using DiFMUO as the substrate (Figure 1D). This was in stark contrast to results 
obtained using membranes derived from the U2OS cell line stably expressing DAGLα-V5 
(V5α11) which were used as controls to validate the assay conditions and were found to be 
significantly more active than the parental membranes in both the PNPB (10-fold) and 
DiFMUO (2-fold) assays when compared to the V5β4 membranes (Figure S1A and B). These 
results indicate that PNPB and DiFMUO are relatively poor substrates of DAGLβ.  To 
investigate this further and in an effort to establish a more robust DAGLβ activity assay, we 
tested the activity of DAGLβ against a third commercially available substrate, EnzChek. An 
improved 3.4 fold difference in activity was observed in the V5β4 compared to the parental 
cell membranes indicating that EnzChek is a more favourable substrate of DAGLβ compared 
to PNPB or DiFMUO. Intriguingly, unlike the PNPB and DiFMUO assays, the V5α11 
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membranes were less active than the V5β4 membranes when using EnzChek as the substrate 
(Figure S1C). 
 
Development of a DAGLβ EnzChek assay using the purified catalytic domain 
In order to generate a relatively clean DAGLβ assay with minimal background activity and a 
homogenous enzyme source, we expressed and purified the N-terminally tagged GST 
catalytic domain of DAGLβ using the baculovirus expression system and GST affinity and 
gel filtration chromatography. Firstly, we conducted an expression time course using 
recombinant baculoviruses containing the GST-DAGLβ CD transgene and Sf9 insect cells. 
48 hours was selected as the harvest time for scale-up batches based on expression levels 
detected in lysates at the predicted molecular weight (~75kDa)  by Western analyses using a 
GST antibody as well as levels of lower molecular weight GST tagged contaminants which 
could prove problematic during purification (Figure 2A).  
Following scaled up expression and GST affinity purification, the elutions were analysed by 
Coomassie stained SDS-PAGE. A prominent band at the predicted size of GST-DAGLβ CD 
was detected in the elutions (Figure 2B). The purity was adjudged to be ~25% with the major 
contaminants detected at ~25kDa. Due to the significant size difference between the major 
contaminants and the GST-DAGLβ CD, gel filtration chromatography was used to further 
purify the enzyme using the HiLoad 16/600 Superdex 200 column. 2ml of the GST elutions 
were subjected to gel filtration chromatography. Any fractions corresponding to peaks in the 
chromatogram (absorbance at 280nm), were analysed by Coomassie stained SDS-PAGE 
(Figure 2C; the fraction numbers correspond to the elution volume). The chromatogram was 
also used to estimate the native molecular weights of the fractions. The activity of the 
fractions was also tested using EnzChek (Figure 2D). The first three pooled fractions 
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contained GST-DAGLβ CD; the first (44-49) and second (50-60) corresponded to a native 
molecular weight >400kDa and were found to be largely inactive thereby indicating that the 
GST-DAGLβ CD present in these samples was aggregated or misfolded.  The third pooled 
fraction (62-68) corresponded to a native molecular weight of ~160kDa and was the most 
active indicating that the sample contained active dimeric GST-DAGLβ CD; the activity was 
largely inhibited by THL (~10-fold THL sensitive window).  The subsequent pooled elutions 
(69-74; 76-80; 81-90) contained lower molecular weight contaminants and/or little or no 
GST-DAGLβ CD/THL sensitive activity. Fraction 62-68 was therefore aliquoted and stored 
at -80°C and used for subsequent experiments. The yield following gel filtration 
chromatography was 220µg/L of culture volume and the estimated purity of the sample was 
~90%.  
In order to optimise a GST-DAGLβ CD EnzChek assay, we first monitored activity rates as a 
function of enzyme concentration. Increasing amounts of enzyme corresponded to increasing 
rates of activity and the signal was found to be linear for the duration of the assay (10 
minutes) (Figure 3A and B). Almost no activity was detected in the absence of GST-DAGLβ 
CD. For further experiments 500ng of enzyme was used per well. We next determined the 
effect of substrate concentration on the rate of activity (Figure 3C). Increasing concentrations 
of EnzChek was associated with increasing rates of activity. The Km and Vmax were 
determined as 4.26±0.32µM and 4.95±0.15 RFU/sec respectively. 
In order to further validate the assay, two established DAGL inhibitors (THL and OMDM-
188) were tested at increasing concentrations. Both compounds inhibited activity in a 
concentration dependent manner with IC50s determined as follows – THL 26.86±4.33nM 
(Hill slope 0.95±0.13) and OMDM-188 6.70±2.05nM (Hill slope 0.79±0.17) (Figure 4). The 
results are consistent with previous DAGLα studies where OMDM-188 was reported as the 
Page 15 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16 
 
more potent DAGL inhibitor 
33,35,36
. The intra and inter-assay coefficient of variations were 
determined as 4.5% (n=4) and 9.8% (N=5) respectively.  
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Discussion 
The DAGLs are emerging targets for a range of diseases and are therefore of great interest for 
drug discovery programmes. Native substrate DAGL assays involve the use of synthetic 
DAG as a substrate coupled with the measurement of 2-AG as the product and generally rely 
on low-throughput mass spectrometry techniques 
26,27
. Other low-throughput thin layered 
chromatography based assays using radio-labelled substrates 
2,28
 and gel based assays using 
activity based probes 
13,27,29,30
 have also been reported. There have been recent reports of 
DAGL activity assays that are amenable to relatively high-throughput screening programmes 
for inhibitors or activators of these enzymes; the assays reported generally employ 
membranes or lysates isolated from cells over-expressing DAGLα 
28,33
and notably include a 
DAGLα native substrate assay using a coupled enzyme approach adapted from a previously 
reported MAGL assay 
31,32
.  
In order to further complement the panel of DAGL activity assays, we report here human 
DAGLβ activity assays using membranes over-expressing the full length enzyme as well as 
its purified catalytic domain. By establishing the U2OScell line (V5β4) that stably and 
robustly express the human DAGLβ transgene, we have developed a consistent tool 
(compared to transiently transfected cells)to directly study human DAGLβ catalytic activity 
and attempted to adapt previously reported DAGLα substrate assays for this purpose 
33
. The 
difference in activity between the V5β4 and parental membranes was higher when using the 
smaller chromogenic PNPB substrate (2 fold) in comparison to the larger fluorogenic 
substrate DiFMUO (no significant difference). Possible explanations for this difference could 
be higher background enzymatic activity in the parental membranes towards DiFMUO when 
compared to PNPB which could especially be problematic as DiFMUO may access the 
DAGLs through the membrane whereas PNPB may access the DAGLs through the aqueous 
phase. If this is the case, then the membrane diffusion rates of DiFMUO could prove to be 
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rate limiting in the context of DAGL activity 
33
. If both substrates were to access the DAGLs 
through the membrane, then different membrane diffusion rates could explain the differences 
in activity. The higher molecular weights of DiFMUO (338Da) when compared to PNPB 
(209Da) may also influence the activity of the DAGLs against these substrates as substrate 
access to the active site of lipases is known to be regulated by a displaceable lid like structure 
37–39
. The smaller PNPB substrate could potentially be less susceptible to steric hindrance by 
the lid when compared to larger substrates. On the contrary, however, the DAGLβ membrane 
assay employing the larger fluorogenic EnzChek substrate (1011Da) was found to be superior 
to the PNPB and DiFMUO assays based on the difference in activity between V5β4 and 
parental membranes (3.5 fold using EnzChek compared to 2 fold using PNPB and no 
significant difference using DiFMUO). As part of the study, membranes derived from the cell 
line stably expressing DAGLα-V5 were employed as controls for the PNPB and DiFMUO 
assays and were found to be much more active than the V5β4 membranes. Establishing 
relative expression levels of DAGLα and DAGLβ in the membranes will help determine 
whether these differences in activity reflect quantitative and/or qualitative differences 
between these two enzyme preparations. Intriguingly, in contrast to the PNPB and DiFMUO 
assays, the V5α11 membranes were less active compared to the V5β4 membranes in the 
EnzChek assay which thereby indicates differences in the catalytic activity of these closely 
related enzymes. More detailed kinetic studies involving the DAGLs and these substrates are 
warranted in order to help elucidate structural details that may contribute to these differences 
in activity, especially as such details could be of potential interest from a medicinal chemistry 
perspective.  
Activity assays involving purified enzymes provide homogenous, consistent, and reliable 
platforms for high-throughput screens by minimizing background and/or non-specific activity 
often observed in crude samples. We successfully expressed and purified the N-terminally 
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GST-tagged catalytic domain of DAGLβ (GST-DAGLβ CD) using the baculovirus 
expression system and GST affinity and gel filtration chromatography achieving yields of 
~0.2 mg/L culture volume and purity of ~90%. As in our case, the baculovirus expression 
system has proven to be a valuable tool for the expression and purification of a range of 
challenging mammalian targets that are too complex and prone to aggregation in the simpler 
prokaryotic E. coli expression system 
40–42
. Activity of GST-DAGLβ CD was confirmed 
using EnzChek (which was the best substrate identified here using DAGLβ membranes) as 
well as two established DAGLβ inhibitors, namely THL, and OMDM-188 
2,27,33
. As far as we 
are aware, this is the first report of the purification of recombinant mammalian DAGL which 
besides its obvious utility in drug discovery assays may also prove valuable for other studies. 
For example, in the absence of crystal structures for the DAGLs, mutagenesis studies coupled 
with activity assays using the substrates described here and in other reports could help 
identify structural features of this enzyme. Moreover, insertion of a cleavage site between the 
GST tag and catalytic domain could enable the purification of the untagged catalytic domain 
for structural studies using X-ray crystallography or other techniques. Additionally, in vitro 
phosphorylation coupled with mutagenesis studies may help elucidate activation mechanisms 
considering that the lid of DAGLβ contains a hyper-phosphorylated region 
39
.  
Future work comparing GST-DAGLβ CD to full length recombinant and endogenous 
DAGLβ will be important to establish further utility for this purified enzyme. For example, 
characterizing GST-DAGLβ CD using the native DAGL substrate 1-stearoyl-2-arachidonoyl-
sn-glycerol will enable comparisons with previously reported Km values for recombinant full 
length DAGLβ (Km 74.1±4.9µM using using sn-1-stearoyl-2-[14C]arachidonoyl-glycerol as 
the substrate) 
2
. Similarly, immunoprecipitation, co-immunoprecipitation, and native SDS-
PAGE studies to determine the oligomeric (or monomeric) status of full length endogenous 
and/or recombinant DAGLβ will be useful as a preliminary quaternary structure comparison 
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with the purified dimeric GST-DAGLβ CD. As far as the activity assay is concerned, 
including product standards within the assay plate will enable the quantification of the 
product and thereby comparisons with activities measured using other DAGL substrates (e.g. 
the native substrate 1-stearoyl-2-arachidonoyl-sn-glycerol).  Determining the Z’ factor of the 
assay will also be important towards validating the assay for high-throughput screening 
campaigns 
43
. It is noteworthy to mention that some serine protease inhibitors like PMSF 
which are commonly used as part of protein purification procedures can also potentially 
inhibit serine hydrolases like the DAGLs and therefore, as part of future efforts, screening 
various protease inhibitors will be advisable to improve the assays performance. 
Characterizing further established (e.g. RHC-80267) as well as recently discovered novel 
DAGL inhibitors in this “clean” and homogenous assay will not only further validate the 
assay but also potentially provide useful information regarding their inhibition kinetics and 
enable comparisons with their DAGLα inhibition profiles 
2,13,34,44,45
. In general, the DAGLβ 
assays described here also have particular utility as selectivity assays. For instance, the 
DAGLs make distinct contributions towards 2-AG (and AA) levels in different tissues e.g. 
DAGLα accounts for most of the 2-AG in the brain, DAGLβ is responsible for most of the 2-
AG in the liver 
7
. The use of selective DAGLβ inhibitors to inhibit eCB signalling might be 
fruitful in certain conditions as it has the potential to avoid the adverse psychiatric effects of 
blocking the pathway at the level of the CB1 receptor 
25
 as it is DAGLα rather than DAGLβ, 
that is responsible for generating 2-AG at synapses 
7
. Similarly, the selective expression of 
DAGLβ in macrophages and microglia makes this enzyme a very interesting therapeutic 
target for inflammatory diseases in both the periphery and central nervous system, and 
importantly this operates independently from the cannabinoid receptors 
13,23,24
.  Targeting 
DAGLα or DAGLβ selectively could therefore be therapeutically attractive, and a further 
understanding of structural and functional differences between these enzymes will be pivotal 
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towards achieving this. Encouragingly, the recent development of a DAGLβ selective 
inhibitor (50 times more potent against DAGLβ than DAGLα) has demonstrated that this is 
indeed achievable from a medicinal chemistry perspective 
13
.    
In conclusion, the relatively simple DAGLβ assays reported here utilizing recombinant 
membranes as well as its purified catalytic domain have great utility for drug discovery 
programmes as a primary (and selectivity) assay with the potential to be adapted for structural 
and mechanistic studies to help further our understanding of this emerging and promising 
anti-inflammatory target.  
Page 21 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22 
 
Acknowledgments 
We thank Dr Roberto Steiner, Dr Stefano Pernigo and Dr Laura Fin for their help and advice 
with the purifications. 
 
Supporting Information Available 
Figure S1 - Characterising DAGLα activity in the V5α11 membranes.  
Supporting materials may be accessed free of charge online at http://pubs.acs.org. 
  
Page 22 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23 
 
References 
(1) Oudin, M. J., Hobbs, C., and Doherty, P. (2011) DAGL-dependent endocannabinoid 
signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis, Eur J 
Neurosci 34, 1634–1646. 
(2) Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., 
Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., 
and Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and 
temporal regulation of endocannabinoid signaling in the brain, J Cell Biol 163, 463–468. 
(3) Williams, E. J., Walsh, F. S., and Doherty, P. (2003) The FGF receptor uses the 
endocannabinoid signaling system to couple to an axonal growth response, J Cell Biol 160, 
481–486. 
(4) Wu, C. S., Zhu, J., Wager-Miller, J., Wang, S., O’Leary, D., Monory, K., Lutz, B., 
Mackie, K., and Lu, H. C. (2010) Requirement of cannabinoid CB(1) receptors in cortical 
pyramidal neurons for appropriate development of corticothalamic and thalamocortical 
projections, Eur J Neurosci 32, 693–706. 
(5) Mulder, J., Aguado, T., Keimpema, E., Barabas, K., Ballester Rosado, C. J., Nguyen, L., 
Monory, K., Marsicano, G., Di Marzo, V., Hurd, Y. L., Guillemot, F., Mackie, K., Lutz, B., 
Guzman, M., Lu, H. C., Galve-Roperh, I., and Harkany, T. (2008) Endocannabinoid signaling 
controls pyramidal cell specification and long-range axon patterning, Proc Natl Acad Sci U S 
A 105, 8760–8765. 
(6) Watson, S., Chambers, D., Hobbs, C., Doherty, P., and Graham, A. (2008) The 
endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation, Mol 
Cell Neurosci 38, 89–97. 
Page 23 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24 
 
(7) Gao, Y., Vasilyev, D. V, Goncalves, M. B., Howell, F. V, Hobbs, C., Reisenberg, M., 
Shen, R., Zhang, M. Y., Strassle, B. W., Lu, P., Mark, L., Piesla, M. J., Deng, K., Kouranova, 
E. V, Ring, R. H., Whiteside, G. T., Bates, B., Walsh, F. S., Williams, G., Pangalos, M. N., 
Samad, T. A., and Doherty, P. (2010) Loss of retrograde endocannabinoid signaling and 
reduced adult neurogenesis in diacylglycerol lipase knock-out mice, J Neurosci 30, 2017–
2024. 
(8) Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., 
Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., and Kano, M. (2010) The 
endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates 
retrograde suppression of synaptic transmission, Neuron 65, 320–327. 
(9) Oudin, M. J., Gajendra, S., Williams, G., Hobbs, C., Lalli, G., and Doherty, P. (2011) 
Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the 
postnatal brain, J Neurosci 31, 4000–4011. 
(10) Goncalves, M. B., Suetterlin, P., Yip, P., Molina-Holgado, F., Walker, D. J., Oudin, M. 
J., Zentar, M. P., Pollard, S., Yanez-Munoz, R. J., Williams, G., Walsh, F. S., Pangalos, M. 
N., and Doherty, P. (2008) A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult 
subventricular zone neurogenesis in an age-dependent manner, Mol Cell Neurosci 38, 526–
536. 
(11) Nomura, D. K., Hudak, C. S., Ward, A. M., Burston, J. J., Issa, R. S., Fisher, K. J., 
Abood, M. E., Wiley, J. L., Lichtman, A. H., and Casida, J. E. (2008) Monoacylglycerol 
lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels, Bioorg Med Chem 
Lett 18, 5875–5878. 
(12) Nomura, D. K., Blankman, J. L., Simon, G. M., Fujioka, K., Issa, R. S., Ward, A. M., 
Page 24 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25 
 
Cravatt, B. F., and Casida, J. E. (2008) Activation of the endocannabinoid system by 
organophosphorus nerve agents, Nat Chem Biol 4, 373–378. 
(13) Hsu, K. L., Tsuboi, K., Adibekian, A., Pugh, H., Masuda, K., and Cravatt, B. F. (2012) 
DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory 
responses, Nat Chem Biol 8, 999–1007. 
(14) Jung, K. M., Sepers, M., Henstridge, C. M., Lassalle, O., Neuhofer, D., Martin, H., 
Ginger, M., Frick, A., DiPatrizio, N. V, Mackie, K., Katona, I., Piomelli, D., and Manzoni, O. 
J. (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile 
X syndrome, Nat Commun 3, 1080. 
(15) Gregg, L. C., Jung, K. M., Spradley, J. M., Nyilas, R., Suplita  2nd, R. L., Zimmer, A., 
Watanabe, M., Mackie, K., Katona, I., Piomelli, D., and Hohmann, A. G. (2012) Activation 
of type 5 metabotropic glutamate receptors and diacylglycerol lipase-alpha initiates 2-
arachidonoylglycerol formation and endocannabinoid-mediated analgesia, J Neurosci 32, 
9457–9468. 
(16) Kunos, G., and Tam, J. (2011) The case for peripheral CB(1) receptor blockade in the 
treatment of visceral obesity and its cardiometabolic complications, Br J Pharmacol 163, 
1423–1431. 
(17) Marco, E. M., Romero-Zerbo, S. Y., Viveros, M. P., and Bermudez-Silva, F. J. (2012) 
The role of the endocannabinoid system in eating disorders: pharmacological implications, 
Behav Pharmacol 23, 526–536. 
(18) McLaughlin, P. J. (2012) Reports of the death of CB1 antagonists have been greatly 
exaggerated: recent preclinical findings predict improved safety in the treatment of obesity, 
Behav Pharmacol 23, 537–550. 
Page 25 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26 
 
(19) Silvestri, C., and Di Marzo, V. (2012) Second generation CB1 receptor blockers and 
other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use 
against metabolic disorders, Expert Opin Investig Drugs 21, 1309–1322. 
(20) Zogopoulos, P., Vasileiou, I., Patsouris, E., and Theocharis, S. E. (2013) The role of 
endocannabinoids in pain modulation, Fundam Clin Pharmacol 27, 64–80. 
(21) Guindon, J., and Hohmann, A. G. (2009) The endocannabinoid system and pain, CNS 
Neurol Disord Drug Targets 8, 403–421. 
(22) Pacher, P., and Kunos, G. (2013) Modulating the endocannabinoid system in human 
health and disease--successes and failures, FEBS J 280, 1918–1943. 
(23) Piro, J. R., Benjamin, D. I., Duerr, J. M., Pi, Y., Gonzales, C., Wood, K. M., Schwartz, J. 
W., Nomura, D. K., and Samad, T. A. (2012) A dysregulated endocannabinoid-eicosanoid 
network supports pathogenesis in a mouse model of Alzheimer’s disease, Cell Rep 1, 617–
623. 
(24) Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, 
M. C., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., and Cravatt, B. F. (2011) 
Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation, 
Science (80-. ). 334, 809–813. 
(25) Moreira, F. A., and Crippa, J. A. S. (2009) The psychiatric side-effects of rimonabant, 
Rev. Bras. Psiquiatr. 31, 145–53. 
(26) Jung, K. M., Astarita, G., Zhu, C., Wallace, M., Mackie, K., and Piomelli, D. (2007) A 
key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent 
endocannabinoid mobilization, Mol Pharmacol 72, 612–621. 
Page 26 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27 
 
(27) Hoover, H. S., Blankman, J. L., Niessen, S., and Cravatt, B. F. (2008) Selectivity of 
inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling, 
Bioorg. Med. Chem. Lett. 18, 5838–41. 
(28) Johnston, M., Bhatt, S. R., Sikka, S., Mercier, R. W., West, J. M., Makriyannis, A., 
Gatley, S. J., and Duclos  Jr., R. I. (2012) Assay and inhibition of diacylglycerol lipase 
activity, Bioorg Med Chem Lett 22, 4585–4592. 
(29) Hsu, K. L., Tsuboi, K., Whitby, L. R., Speers, A. E., Pugh, H., Inloes, J., and Cravatt, B. 
F. (2013) Development and optimization of piperidyl-1,2,3-triazole ureas as selective 
chemical probes of endocannabinoid biosynthesis, J. Med. Chem. 56, 8257–69. 
(30) Baggelaar, M. P., Janssen, F. J., van Esbroeck, A. C. M., den Dulk, H., Allarà, M., 
Hoogendoorn, S., McGuire, R., Florea, B. I., Meeuwenoord, N., van den Elst, H., van der 
Marel, G. A., Brouwer, J., Di Marzo, V., Overkleeft, H. S., and van der Stelt, M. (2013) 
Development of an activity-based probe and in silico design reveal highly selective inhibitors 
for diacylglycerol lipase-α in brain, Angew. Chem. Int. Ed. Engl. 52, 12081–5. 
(31) van der Wel, T., Janssen, F. J., Baggelaar, M. P., Deng, H., den Dulk, H., Overkleeft, H. 
S., and van der Stelt, M. (2015) A natural substrate-based fluorescence assay for inhibitor 
screening on diacylglycerol lipase α, J. Lipid Res. 56, 927–35. 
(32) Navia-Paldanius, D., Savinainen, J. R., and Laitinen, J. T. (2012) Biochemical and 
pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 
12 (ABHD12), J. Lipid Res. 53, 2413–24. 
(33) Pedicord, D. L., Flynn, M. J., Fanslau, C., Miranda, M., Hunihan, L., Robertson, B. J., 
Pearce, B. C., Yu, X. C., Westphal, R. S., and Blat, Y. (2011) Molecular characterization and 
identification of surrogate substrates for diacylglycerol lipase alpha, Biochem Biophys Res 
Page 27 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28 
 
Commun 411, 809–814. 
(34) Appiah, K. K., Blat, Y., Robertson, B. J., Pearce, B. C., Pedicord, D. L., Gentles, R. G., 
Yu, X.-C., Mseeh, F., Nguyen, N., Swaffield, J. C., Harden, D. G., Westphal, R. S., Banks, 
M. N., and O’Connell, J. C. (2014) Identification of small molecules that selectively inhibit 
diacylglycerol lipase-α activity, J. Biomol. Screen. 19, 595–605. 
(35) Bisogno, T., Cascio, M. G., Saha, B., Mahadevan, A., Urbani, P., Minassi, A., 
Appendino, G., Saturnino, C., Martin, B., Razdan, R., and Di Marzo, V. (2006) Development 
of the first potent and specific inhibitors of endocannabinoid biosynthesis, Biochim Biophys 
Acta 1761, 205–212. 
(36) Ortar, G., Bisogno, T., Ligresti, A., Morera, E., Nalli, M., and Di Marzo, V. (2008) 
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol 
metabolism, J Med Chem 51, 6970–6979. 
(37) Nardini, M., and Dijkstra, B. W. (1999) Alpha/beta hydrolase fold enzymes: the family 
keeps growing, Curr Opin Struct Biol 9, 732–737. 
(38) Holmquist, M. (2000) Alpha/Beta-hydrolase fold enzymes: structures, functions and 
mechanisms, Curr Protein Pept Sci 1, 209–235. 
(39) Reisenberg, M., Singh, P. K., Williams, G., and Doherty, P. (2012) The diacylglycerol 
lipases: structure, regulation and roles in and beyond endocannabinoid signalling, Philos 
Trans R Soc L. B Biol Sci 367, 3264–3275. 
(40) Hassan, N. J., and Gul, S. (2011) Strategies to generate biological reagents for kinase 
drug discovery, Expert Opin. Drug Discov. 6, 1215–25. 
(41) Hassan, N. J., Gul, S., Flett, F., Hollingsworth, E., Dunne, A. A., Emmons, A. J., 
Page 28 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
29 
 
Hutchinson, J. P., Hibbs, M. J., Dyos, S., Kitson, J. D., Hiley, E., Rüdiger, M., Tew, D. G., 
Powell, D. J., and Morse, M. A. (2009) Development of an insect-cell-based assay for 
detection of kinase inhibition using NF-kappaB-inducing kinase as a paradigm, Biochem. J. 
419, 65–73. 
(42) Singh, P. K., Chan, P. F., Hibbs, M. J., Vazquez, M. J., Segura, D. C., Thomas, D. A., 
Theobald, A. J., Gallagher, K. T., and Hassan, N. J. (2011) High-yield production and 
characterization of biologically active GST-tagged human topoisomerase IIα protein in insect 
cells for the development of a high-throughput assay, Protein Expr. Purif. 76, 165–172. 
(43) Zhang, J., Chung, T., and Oldenburg, K. (1999) A Simple Statistical Parameter for Use 
in Evaluation and Validation of High Throughput Screening Assays., J. Biomol. Screen. 4, 
67–73. 
(44) Baggelaar, M. P., Chameau, P. J. P., Kantae, V., Hummel, J., Hsu, K.-L., Janssen, F., 
van der Wel, T., Soethoudt, M., Deng, H., den Dulk, H., Allarà, M., Florea, B. I., Di Marzo, 
V., Wadman, W. J., Kruse, C. G., Overkleeft, H. S., Hankemeier, T., Werkman, T. R., 
Cravatt, B. F., and van der Stelt, M. (2015) Highly Selective, Reversible Inhibitor Identified 
by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons, J. 
Am. Chem. Soc. 137, 8851–7. 
(45) Chupak, L. S., Zheng, X., Hu, S., Huang, Y., Ding, M., Lewis, M. A., Westphal, R. S., 
Blat, Y., McClure, A., and Gentles, R. G. (2016) Structure activity relationship studies on 
chemically non-reactive glycine sulfonamide inhibitors of diacylglycerol lipase., Bioorg. 
Med. Chem. 24, 1455–68. 
  
Page 29 of 36
ACS Paragon Plus Environment
Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30 
 
Figure legends 
Figure 1. Characterising DAGLβ expression and activity in the V5β4 membranes  
A representative image of fixed V5β4 cells immunostained with a V5 antibody (green) and 
the nuclear stain Hoechst (blue) is shown above, demonstrating the stable and clonal 
expression of DAGLβ-V5 (A). A representative Western blot image of membranes (10µg) 
isolated from V5β4 cells is also shown, confirming DAGLβ-V5 expression at a size close to 
the predicted molecular weight (75kDa) (B). Parental cells/membranes were included as a 
negative control for both analyses. The activity of membranes (12.5µg/ml) isolated from the 
V5β4 cells or parental cells was measured using PNPB (250µM) (mean±SEM, V5β4 n=9, 
parental n=13) (C) or DiFMUO (10µM) (mean±SEM, V5β4 n=4, parental n=8) (D) in the 
presence or absence of THL (1µM); reaction rates were calculated over the first 10 minutes 
and the THL sensitive activity is presented above. Activity of the membranes was also 
measured using a third substrate, EnzChek (2µM). The reaction rates were calculated over the 
first two minutes (mean±SEM, n=3) and the THL sensitive activity detected is presented 
above (E). ** p<0.01, * p<0.05 (two tailed t-test). 
 
Figure 2. Expression and purification of GST-DAGLβ CD  
Lysates of Sf9 cells expressing GST-DAGLβ CD was analysed at different time points by 
Western blotting using a GST antibody which revealed 48 hours as the optimum time point 
(A). For the GST affinity purification, clarified lysates obtained from insect cells expressing 
GST-DAGLβ CD were incubated with glutathione sepharose 4B beads; bound protein was 
eluted using 50mM glutathione and elutions were analysed by Coomassie stained SDS-PAGE 
(B).  2mls of the elutions from the GST affinity purification were loaded onto the HiLoad 
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16/600 Superdex 200 column (gel filtration purification). Fractions corresponding to peaks 
observed in the chromatogram (absorbance at 280nm) were collected and the corresponding 
Coomassie stained SDS-PAGE analysis (20µl) of the fractions is presented above (C). The 
first three sets of pooled fractions contained GST-DAGLβ CD. Activity of these fractions 
was tested using EnzChek (2µM) in the presence or absence of THL (1µM); the reaction rates 
were calculated over 10 minutes and are presented above (mean of 3 wells ±SEM). THL 
sensitive activity was largely detected in fractions 62-68 (D).  
 
Figure 3. Development of a GST-DAGLβ CD activity assay 
The activity of different amounts of GST-DAGLβ CD following GST affinity and gel 
filtration chromatography was measured using EnzChek (2µM) by measuring the 
fluorescence (excitation 480nm, emission 540nm) every 48 seconds for 10 minutes. 
Increasing amounts of enzyme corresponded to increasing rates of activity measured over 10 
minutes (mean of 3 wells ±SEM) (A) during which the reaction was found to be linear (B). 
The activity of 500ng GST-DAGLβ CD was tested with different concentrations of EnzChek 
as mentioned above (mean of 3 wells ±SEM) (C). Km was determined as 4.89±0.66µM. 
 
Figure 4. Inhibition of GST-DAGLβ CD activity  
The activity of GST-DAGLβ CD (500ng) following GST affinity and gel filtration 
chromatography was measured using EnzChek (2µM) by measuring the fluorescence 
(excitation 480nm, emission 540nm) every 48 seconds for 10 minutes in the presence of two 
DAGL inhibitors. Both compounds, namely THL and OMDM-188 (mean±SD, n=2) were 
found to inhibit activity. 
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Figure 2. Expression and purification of GST-DAGLβ CD  
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Figure 3. Development of a GST-DAGLβ CD activity assay  
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Figure 4. Inhibition of GST-DAGLβ CD activity  
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